Correction to: Neck cooling induces blood pressure increase and peripheral vasoconstriction in healthy persons

A Correction to this paper has been published: https://doi.org/10.1007/s10072-021-05355-3

SAFETY OF USE OF HIGH ALTITUDE PROTECTION SUITS FOR KINESITHERAPY – PRELIMINARY REPORT

Apart from protection from very high altitude or influence of increased gravitational accelerations protective suits sometimes are used for another applications like supporting kinesitherapy. Because of some safety considerations connected with possible cardiovascular system overload and dangerous blood pressure increase we tested if these concerns are valid. Main aim ot presented research performed with participation of healthy volunteers was to confirm that use of High Altitude Protection (HAP) suit is safe in terms of increased cardiovascular.

Drug Related Hypertension: A Review on an Unappreciated Cause of Blood Pressure Increase

Blood pressure elevation is known to be a determining risk factor for cardiovascular disease and mortality. Although blood pressure increase has many causative factors, numerous drugs have also been reported to increase blood pressure. Drugs are often overlooked as a reason of hypertension. A few medications that usually help to reduce blood pressure may increase blood pressure paradoxically or may lead to blood pressure elevation on discontinuation due to a rebound effect. Detailed evaluation of patient’s medical therapy may help to identify the culprit drug. Discontinuation of the causative agent is recommended once the drug induced hypertension has been identified. The present review summarizes the therapeutic agents that can induce hypertension and would allow the clinician to recognize this entity and to take the appropriate therapeutic measures.

Elevated IL 23 in Hypertensive Patients with Acutely Increased Blood Pressure

Background As a chronic medical condition characterized by elevated blood pressure, hypertension is recognized as a major risk factor for a variety of life threatening diseases including stroke, myocardial infarction, heart failure and aortic aneurysm. And most of these severe complications occur in the hypertensive patients with a sudden increase of blood pressure. Aim of the Work The aim of this study is To evaluate the role of IL23 in the immune pathogenesis of hypertension. Subjects and Methods This was a prospective Case-Control study was carried out in the Internal Medicine Department, faculty of medicine, Ain Shams university hospital during the period from November 2016 to December 2017.In this study we performed full history taking and examination, we also performed complete blood count, liver function tests, kidney function tests, estimation of IL23 level in plasma by ELISA in peripheral blood by Flowcytometry. Forty five adult individual were recruited in the study and were further divided into three groups according to the symptoms of blood pressure as follow:group A patients with acute increase of blood pressure, group B patients without acute increase of blood pressure.and group C healthy volunteers with normal blood pressure as control Results we found that mean of IL23/CD4% was higher in group A, followed by group B then group C, all these differences was high significant Conclusion We demonstrated that IL-23 may be involved in the pathogenesis of acute blood pressure increase in the patients with hypertension. Understanding its inflammatory characterization might be of fundamental importance for the prevention and treatment of acute blood pressure increase in hypertensive patients.

Recurrent Blood Pressure Rise after Treatment with Anti-vascular Endothelial Growth Factor Agents

Background It has previously been shown that the process of anti-vascular endothelial growth factor (VEGF) injections can lead to a significant increase of blood pressure. The aim of this study was to investigate whether this blood pressure increase was reproducible with repeated anti-VEGF injections. Patients and Methods Patients with a systolic blood pressure of ≥ 180 mmHg during previous injections who were scheduled for further injections were asked to participate in this study. Systolic as well as diastolic blood pressure was measured before, during, and after the intravitreal injection process. Results Thirty-nine patients (21 females, 18 males) with a mean age of 75 years (range 34 – 94 years) were included in this extension of the FEAR study. At first, clinical systolic blood pressure rose from an average of 157.3 ± 5.9 mmHg to 175 ± 6.7 mmHg at the time of the injection process (p < 0.01). Diastolic blood pressure rose from an average of 75.72 ± 4.2 mmHg to 84.44 ± 7.3 mmHg (p < 0.13) at the time of the injection process. Overall, the majority of the participants (56%, N = 22) had a systolic blood pressure of ≥ 180 mmHg. Conclusions Our results show that the blood pressure increase occurs persistently during the injection process in some patients. Repeated episodes of severe hypertension may predispose patients to cardiovascular events, especially those with concomitant cardiovascular risk factors.